List view / Grid view
7 November 2014 | By AstraZeneca
AstraZeneca announced that MedImmune, its global biologics research and development arm, has entered into an agreement to acquire Definiens, a privately-held company that has pioneered a world-leading imaging and data analysis technology, known as Tissue Phenomics™, which dramatically improves the identification of biomarkers in tumour tissue...
20 October 2014 | By AstraZeneca
AstraZeneca, together with its global biologics research and development arm, MedImmune, announced that it has entered into four new collaborations with the University of Cambridge, building further on their existing partnership...
25 September 2014 | By AstraZeneca
AstraZeneca announced that MedImmune, its global biologics research and development arm, and Cancer Research UK, with its commercial arm, Cancer Research Technology (CRT), have entered into an innovative collaboration to establish a joint laboratory in Cambridge, UK...
22 July 2014 | By AstraZeneca
AstraZeneca announced that MedImmune has entered into a clinical trial collaboration with Advaxis, Inc., a US-based biotechnology company developing cancer immunotherapies...
14 May 2014 | By AstraZeneca
AstraZeneca announced that MedImmune, its global biologics research and development arm, has entered into a clinical study collaboration with biopharmaceutical company Incyte Corporation...
8 January 2014 | By AstraZeneca
Both companies will research and develop novel cancer therapies using Immunocore’s Immune Mobilising Monoclonal T-Cell Receptor Against Cancer (ImmTAC) technology...
15 October 2013 | By AstraZeneca
Additional investment in and collaboration with ADC Therapeutics...
26 August 2013 | By AstraZeneca
AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a definitive agreement to acquire Amplimmune...
17 June 2013 | By AstraZeneca
MedImmune and NGM Biopharmaceuticals have entered into an exclusive agreement...
3 April 2013 | By AstraZeneca
AstraZeneca announced that MedImmune has acquired AlphaCore Pharma, an Ann Arbor, Michigan-based biotechnology company...
18 December 2012 | By Theresa LaVallee, Senior Director, Translational Medicine Oncology, MedImmune
The development of biologic therapies has significantly shifted the treatment paradigm in medicine, particularly in oncology. Groundbreaking research over the past 20 years has sparked new ways of thinking about disease pathology and opened the door for novel targeted therapies that have truly revolutionised medical care. In more recent years,…
22 October 2012 | By Bahija Jallal, Executive Vice President, Research & Development, MedImmune
The first biologic drug – infliximab (Remicade) – was launched in 1998 with initial sales of USD 500 million per annum. By 2010, Reuters’ top 10 drugs by sales included five biologics (Remicade, Enbrel, Humira, Avastin and Humira) generating around USD 34 billion in revenue, including USD 7.4 billion from…
1 March 2012 | By AstraZeneca
MedImmune, has received approval from the US FDA for FluMist® Quadrivalent (Influenza Vaccine Live, Intranasal) in the prevention of influenza...
16 February 2011 | By Bahija Jallal, Executive Vice President, Research & Development, MedImmune
When the term ‘translational medicine’ first came to prominence at the turn of the century, there were suspicions that this concept was simply a rebranding of conventional medical research, describing the process in which scientific discovery at the laboratory bench eventually translates to an effective therapy at the patient’s bedside.…
